drugset / Trial / NCT03338777
Suicide Plus Immune Gene Therapy for Advanced Melanoma
Phase 0
Terminated
4 enrolled
Hospital Italiano de Buenos Aires
Instituto de Oncología Ángel H. Roffo · collabNational Agency for Scientific and Technological Promotion, Argentina · collabNational Council of Scientific and Technical Research, Argentina · collabUniversity of Buenos Aires · collab
NaSingle-groupOpen-labelTreatment
Summary
Safety evaluation of combined immunogene therapy in patients with advanced melanoma.
Timeline
- Start
- 2020-02-20
- Primary completion
- 2020-02-20
- Completion
- 2020-02-20
Outcome
Outcome not reported
Stopped: “Failure to achieve primary objective”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CELMOLEUKIN | Protein / enzyme biologic | 0.5 mg | Subcutaneous |
| Subject | HSV-Tk | Cell therapy | — | Other |
| Subject | LGvax | Vaccine | — | Subcutaneous |
| Subject | hGM-CSF | Protein / enzyme biologic | 0.5 mg | Subcutaneous |
| Background | Ganciclovir | Small molecule | — | — |